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Mechanisms of aluminum-induced microcytosis: Lessons from acciden-
tal aluminum intoxication. Twenty-three hemodialysis patients exposed to
an accidental aluminum overload, showed increased erythropoietin re-
quirements and decreased erythrocyte mean corpuscular volume (MCV).
At the peak of the intoxication, MCV and plasma aluminum levels
changed from unrelated (r = 0.02) to strongly related (r = 0.425)
variables. The molar proportion of plasma aluminum to plasma iron
increased dramatically (from 1:13.8 to 1:2.4). This significant increment in
the aluminum/iron ratio made higher the relative offer of aluminum with
respect to iron to the eiythroid precursor cells. Accordingly, in a subset of
13 randomly selected aluminum-intoxicated patients we found increased
intraerythrocytic aluminum, which paralleled the increase in plasma
aluminum. Furthermore, in the aluminum-intoxicated group, intraeryth-
rocytic ferritin, a marker of iron content, and the ratio between erythro-
cyte and plasma ferritin were lower (P < 0.01 and <0.001, respectively),
than in the control group. These findings support the hypothesis that in
some cases of aluminum-related microcytosis, a ferropenic mycrocitosis,
as expression of erythroid ferropenia, may exist in spite of the presence of
normal body iron stores.
Aluminum-related microcytosis was first recognized in groups
of patients undergoing dialysis therapy with improperly prepared
water [1—4]. Since then, as a consequence of the generalization of
adequate water treatment this complication decreased rapidly;
however, aluminum intoxication still needs to be ruled out as a
cause of anemia or resistance to erythropoietin in dialysis patients
[5, 6].
The current concept about the pathogenesis of aluminum-
related microcytosis is that aluminum might interfere with iron
kinetics at different levels, including alterations in delta amino
levulinic dehydrase activity and intermediate porphyrin products
[7—11], and impaired intestinal iron absorption and cellular up-
take [12].
In the summer of 1993 we had a unique opportunity to examine
a group of patients treated in an independent, extra-Hospitalary
dialysis facility, who presented an important, but not massive,
increase in plasma aluminum levels. During a seven-month ob-
servation period, data were obtained which illustrate, in an unique
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situational model, several issues of human aluminum intoxication.
These data may contribute to understanding the pathogenetic
mechanism of aluminum-related microcytic anemia.
Methods
Patients
In July 1993, a failure in the water treatment system of an
independent dialysis facility, which consisted of an inadequate
connection of the reverse osmosis system, was identified. The
failure allowed some amount of non-treated water to reach the
patient's dialysis bath. Until this exposure, the current policy was
to check the patient's and dialysis fluid's aluminum concentrations
evesy six months. The last aluminum determination of dialysis
fluid was <10 igIliter, and the aluminum concentration in the
dialysis fluid by the time of detection of the failure was 44.7 3.4
jig/liter. Therefore, even though the exact length of the exposure
is difficult to determine, it could have lasted for a maximum of six
months.
In phase 1 (see below), we studied an initial group of 23 patients
(15 males and 8 females), who were exposed to the high aluminum
concentration. During the time of the study, no significant
changes in the treatment were introduced, except for increments
in the dose of erythropoietin needed to achieve an hematocrit of
around 30%. No patient had received aluminum-containing phos-
phate binders at any time for the previous two years. The 23
aluminum-exposed patients did not show classical symptoms of
aluminum intoxication, with the exception of a few observations of
lesions of porphyria cutanea; these are the subject of a separate
study (Mosquera et al, unpublished data). In view of the results
obtained by comparing the data at time I with those at time II,
further studies were done in a randomly assigned subgroup of 13
patients (Phase 2), as detailed below, comparing them with an
age- and sex-matched control group formed by 10 patients of the
University Hospital who were dialyzed during the treatment time
with a dialysis fluid containing less than 10 jsg/liter of aluminum.
The biochemical and hematological data were obtained by
routine methods (SMAC-20 and Coulter S plus VI). Transferrin
was measured by an immunonephelometric method (Behring-
werke A.G., Marburg, Germany) and total iron-binding capacity
was calculated from this measurement. Iron was determined by
the Ferrozine/Guanidine method (Hoffman La Roche, Basel,
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Switzerland). Aluminum was measured as described in previous
reports [12—14] by atomic absorption spectrometry in a specially
prepared clean room Class 100. The detection limit of the method
was 1 pg/liter, and the coefficient of variation was lower than 3%
[12—14].
Intraerythrocytic aluminum was measured in red cells obtained
from heparinized blood using aluminum-free tubes and pipettes
washed and centrifuged twice with saline buffer, to eliminate
blood cells other than ei-ythrocytes. Erythrocytes were lysed using
an aqueous solution containing Tryton X-100 (1%) and EDTA (1
mM), and aluminum was measured in the lysate. No significant
amounts of aluminum were detected in the vehicles; heparin was
used for blood sampling.
Ferritin determinations were done using a double antibody
radioimmunoassay (Nichols Institute, San Juan Capistrano, Cali-
fornia, USA). In phase 2, in the subgroup of 13 patients, we
simultaneously measured ferritin in plasma and erythrocytes by a
modification of previously described methods [15, 16]. Blood was
treated similarly as described in the paragraph above, except that
routine plastic tubing was used.
Design of the study
Phase 1. Three sets of laboratory data were compared, corre-
sponding to: (1) three months previous to the aluminum exposure,
in which the aluminum content of the dialysis water was <10
.tg/J.iter; (II) at the time of the detection and repair of the failure
in the water treatment system (maximum aluminum exposure);
and (III) four months after the repair of the water treatment
system. During this latter period, the patients were dialysed
against an aluminum concentration bath of less than 10 jg/1iter.
Phase 2. Additional determinations were performed in a
smaller, randomly selected group of 13 patients. These determi-
nations of intracellular ferritin and intracellular aluminum were,
however, done after one month of treatment against a low
aluminum bath. Since the present study was organized in the
emergency circumstances of the sudden discovery of an aluminum
intoxication, no preparatory arrangements could be done to
perform a systematic study of all the possibly relevant variables in
all the patients. Furthermore, it was ethically mandatory to repair
the technical failure in the shortest time possible. These circum-
stances may introduce some limitations in interpreting the results
of erythrocyte aluminum and ferritin.
Data analysis
Results are presented as mean SEM. Changes in variables
were analyzed by one-way and two-way analysis of variance for
repeated measures and subsequent Scheffé test. Comparisons
between two groups of data were done by Student's f-test for
paired and unpaired observations (two tails). Comparisons be-
tween two numerical variables were done by regression analysis
and slopes were compared by t-test when appropriate. A P value
of <0.05 was considered significant.
Results
Phase 1
From period I to period II there was a significant increase in
serum aluminum levels from 31.9 4.6 to 147.3 11.7, P <
0.0001, and a decrease in MCV from 88.3 1.5 to 81.5 1.7, both
P < 0.0001. In the same periods no significant change was found
MCV, p9
Fig. 1. Phase 1. Relationship by regression analysis between plasma
aluminum levels and MCV at three different times: before aluminum
intoxication (, period I); at the time of detection of aluminum intoxi-
cation (-.-, maximum Al levels, period II); and four months after the
returning to normal aluminum concentrations (—tx—, <10 jsg/L, period III)
in the dialysis fluid. The regression lines corresponding to times II and III
were significantly different with respect to period I (P = 0.008).
in plasma iron (82.7 11.8 to 72.3 6.5), plasma transferrin
(283.3 17 to 251.6 11.2), iron transferrin saturation (31.7
4.04 to 30.8 3.0), or serum ferritin (494 160 to 404.3 129.8).
In addition, to maintain a constant hematocrit (Period I: 30.6
0.5, Period II: 30.4 0.6), we also observed a significant (P =
0.0047) increment in the requirements of human erythropoietin
(from 5542 722 units in Period Ito 7344 910 units to period
II). In period I there was no relationship between MCV and
serum aluminum (r = 0.02); by contrast, in period II, there was a
significant inverse relationship between both parameters, (P <
0.001, Fig. 1). Four months after the correction of the water
treatment failure (Period III), an additional comparison between
serum aluminum and MCV was performed. As it can be also
observed in Figure 1, the group had partially corrected their
values, even though they still had significant differences (P <
0.001) with respect to the baseline MCV/aluminum relationship.
When we analyzed on a molar basis, the proportion of both metals
in serum, we found a significant increase in the Al/Fe ratio in
period II with respect to period I (Fig. 2).
Phase 2
The comparative data of intraerythrocytic and plasma alumi-
num and ferritin in the subset of 13 patients are shown in Table 1.
The intraerythrocytic and serum aluminum levels were signifi-
cantly higher in aluminum-intoxicated patients in whom a signif-
icant negative relationship persisted between these two parame-
ters and MCV (intraerythrocytic vs. MCV r = 0.371, P = 0.027;
serum Al vs. MCV r = 0.393, P = 0.021). No statistical relation-
ship was found between these parameters in the control group. In
addition, the levels of intraerythrocytic ferritin were significantly
lower (P < 0.05) in the aluminum-intoxicated patients (Table 1).
When expressed in attog/cell, those values were 2.2 0.5
and 5.3 0.7 for aluminum-intoxicated and control patients,
respectively (P = 0.023). The ratio between intraeiythrocytic and
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Fig. 2. Phase 1. Plasma Al/Fe ratio before and after the detection of
aluminum load (period I 0.093 0.021 vs. period II 0.521 0.083). *P <
0.0001 between periods I and II.
Table 1. Phase 2
Al
intoxicated
patients
Control
patients P
Erythrocyte Al pg/kg 133.1 14.4 31.08 3.2 <0.0001
Plasma Al pg/liter 110.2 11.6 26.2 4.26 <0.0001
Erythrocyte ferritin ng/ml 33.4 4.01 93.3 24.7 0.012
Plasma ferritin ng/ml 338.6 149 167.1 52.7 NS
Comparative data of intraerythrocytic and plasma aluminum and fer-
ritin in 13 aluminum-intoxicated patients and 10 controls. All P values
correspond to differences between control and aluminum-intoxicated
patients.
plasma ferritin showed a marked decrease in aluminum-intoxi-
cated patients compared with controls (Fig. 3).
Discussion
The occurrence of an accidental aluminum intoxication in a
Dialysis Unit offered a unique opportunity for studying the
interactions between aluminum and iron kinetics in a evolving
situation in human subjects. The reports published to date on the
role of aluminum as a cause of microcytic anemia correspond
to series of patients treated chronically with high aluminum-
containing dialysate and, therefore, little comparison could be
done with previous baseline controls in the same patients [2—4].
This fact made difficult to analyze the pathogenetic conditions
involved in the appearance of microcytosis. In addition, most of
the previous studies corresponded to the pre-rHuEPO era.
Short, Winney and Robson have proposed that anemia may be
the first manifestation of aluminum overload [2]. More recently,
aluminum overload was related by other authors with the appear-
ance of augmented needs of rHuEPO [5, 6]. Our findings are in
agreement with these previous reports, showing the appearance of
microcytosis and a significant increase in the rHuEPO require-
ments after a period of aluminum overload.
The main observations in the patients analyzed herein include
the hematological differences found after the aluminum exposure.
Fig. 3. Phase 2. Intraerythrocytic and plasma ferritin ratio in aluminum-
intoxicated patients (N = 12) and controls (N = 10). P = 0.03 between
groups. For this comparison, ferritin was expressed as ng/ml of plasma and
ng/ml packed red blood cells (Al-intoxicated patients 0.131 0.032 vs.
control patients 0.486 0.081).
The highly correlated relationship between MCV and plasma
aluminum, the higher intraerythrocytic aluminum with respect to
plasma aluminum, and the lower intraerythrocytic ferritin com-
pared with plasma ferritin, are the three main findings which allow
us to interpret the pathogenetic sequence of the microcytic
anemia of these patients.
Plasma ferritin level is a well-known marker of the total
magnitude of iron stores, but it is not as good marker of the
amount of iron offered to the erythroid precursors [14—16]. The
measurement of the intraerythrocytic ferritin in the present study
has permitted an additional insight in the process of iron acqui-
sition by the erythroid precursors in conditions of aluminum
intoxication.
The hypothesis that aluminum might cause anemia by prevent-
ing iron from binding or unloading from transferrin was originally
raised in 1983 by Trapp [17]. The data obtained here show that
the aluminum load did not have a specific effect in reducing the
capacity of transferrin to transport iron, but it probably altered the
offer of iron to its target cells, namely, the erythrocyte precursors.
High transferrin saturation by iron has been viewed as a
limitating factor for increasing aluminum transport by the same
transferrin molecules. In previous studies, Cannata et al have
found a significant inverse relationship between serum iron and
transferrin saturation versus serum aluminum in 127 dialysis
patients. However, it is important to note that sharing sites for
plasma iron and aluminum transport without one metal displacing
the other should be possible every time that an incomplete iron
transferrin saturation exists [10].
Cellular transferrin uptake occurs mostly in the occupied form,
the uptake of apotransferrin being markedly smaller than metal-
lotransferrin [19]. As demonstrated by Mladenovic, transferrin
was needed for the appearance of aluminum toxicity on human
erythroid [20]. Aluminum alone, even at very high levels, did not
significantly affect erythroid colony growth. Moreover, inhibition
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by aluminum was found to be directly related to the number of
binding sites on transferrin, and was not observed in the presence
of fully iron-saturated transferrin [20]. The scarce information
available on the comparative uptake kinetics of iron-bound re-
spect to aluminum-bound transferrin suggests that no significant
differences in cellular uptake exist between both forms of metal-
lotransferrin.
Cochran et al have found that human retyculocytes do not
distinguish between aluminum-transferrin and iron-transferrin,
and even that the aluminum transferrin metalloprotein complex is
retained longer within these cells [21], thus generating a greater
accumulation of aluminum transferrin than iron transferrin. Also,
Romero et al postulated that the improvement of anemia ob-
served with deferoxamine in dialysis patients with low aluminum
levels may be due to the displacement of the aluminum molecules
from transferrin and their replacement by iron [22]. Nowadays,
with the use of rHuEPO, there is a greater consumption of the
iron stores, the patients tend to decrease iron transferrin satura-
tion, and therefore, they could offer a larger number of binding
sites to form aluminum transferrin.
In the present set of patients, in the presence of aluminum
overload more molecules of aluminum were probably offered by
transferrin to the erythroid cells, reaching a proportion of approx-
imately 1 to 2.4 aluminum to iron molecules. On the contrary, in
baseline conditions, in the same patients the proportion of
aluminum to iron on a molar basis was approximately 1 to 13.8.
Moreover, the increased intraeiythrocytic aluminum and the
reduction in intraerythrocytic ferritin suggests the presence of a
definite change in the uptake of these metallic elements by the
erythroid cells. The decrease in the erythrocyte:plasma ferritin
ratio in the patients with aluminum intoxication strongly suggests
the existence of a depressed level of iron uptake, in spite of the
normal/high size iron stores represented by the plasma ferritin.
Even though the decrease in erythrocyte ferritin is not a measure-
ment of the erythrocyte iron content, it should be accepted as
representative of the amount of cell iron insofar as most of
intracellular iron is complexed with ferritin.
The present data support previous experimental observations of
decreased iron absorption and iron cellular uptake in aluminum
overload, which raised the hypothesis that the microcytosis ac-
companying aluminum overload could be a significant form of
iron deficiency, despite the existence of normal serum ferritin
levels [23]. In agreement with the present results, the previous
studies did not find differences in serum ferritin, but the degree of
the anemia achieved was enough to stimulate the increase in
serum transferrin [23]. By contrast, the present results did not
favor the in vitro observation by Abreo, Glass and Sella of an
increased iron uptake by Friend's erythroleukemia cells in the
presence of aluminum [24], but they are in agreement with further
data from the same authors, showing changes in iron compart-
mentalization and reduction in the cell content of ferritin [25].
As previously mentioned, aluminum produces some sort of
interference in heme synthesis, which is mostly based in changes
in the activity of enzymes involved in heme synthesis [7, 8, 11].
However, similar changes can also be found in classical iron
deficiency [26]. Bia et al have postulated that the decreased red
cell production and elevated red blood cell protoporphyrin in
patients with modest degree of aluminum overload suggest that an
effect in iron utilization is involved in aluminum-related anemia
[11]. Nevertheless, these and other authors [7, 9, 11] hypothesized
that this defect was not due to ferropenia, based in the finding of
normal plasma ferritin and bone marrow staining for iron. As can
be deduced from other studies [5, 6, 9] and from the present
results, measurement of plasma ferritin alone may be insufficient
to evaluate the real amount of iron which is being offered to the
erythroid precursors. Therefore, though a direct toxic effect of
aluminum on heme synthesis cannot be ruled out, our findings
raise the possibility that aluminum-transferrin may convey the
wrong metal to the erythrocyte precursors, providing an alterna-
tive pathogenetic explanation for the aluminum-related microcy-
tosis,
Finally, another important message from our results is related
to the epidemiological aspects of aluminum levels in dialysis
fluids. We believe it is necessary to insist on the importance of
very frequent, preferably monthly, controls of the quality of the
water treatment in Dialysis Units aiming to achieve permanent
levels of aluminum in the dialysis fluids lower than 5 j.tg/liter [27,
281. This safety policy will decrease the always present possibility
of aluminum intoxication. In this regard, moderate degrees of
aluminum toxicity, as that described in the present study, can be
easily and effectively prevented.
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